Baseline demographic and disease characteristics before the third vaccination
| Parameter . | Patients with CLL (n = 172) . |
|---|---|
| Age at third vaccination, median (IQR), (y) | 72.1 (68.1-77.7) |
| ≤65 y, n (%) | 33 (19.1) |
| Males n (%) | 121 (69.9) |
| Binet stage,* n/N (%) | |
| A | 32/48 (66.7) |
| B | 11/48 (22.9) |
| C | 5/48 (10.4) |
| IGHV mutational status, n/N (%) | |
| Mutated | 41/112 (36.6) |
| Unmutated | 71/112 (63.4) |
| FISH Döhner scale, n/N (%) | |
| Del(13q) | 38/144 (26.4) |
| No aberration | 33/144 (22.9) |
| Trisomy12 | 23/144 (16.0) |
| Del(11q) | 28/144 (19.4) |
| Del(17p) | 22/144 (15.3) |
| Laboratory parameters | |
| White blood cells, median (IQR), (109/L) | 8.9 (5.4-32.9) |
| Hemoglobin, median (IQR), (g/dL) | 13.2 (12.3-14.5) |
| <10 g/dL, n (%) | 10 (6.3) |
| Absolute lymphocyte count, median (IQR), (109/L) | 2.4 (1.3-12.0) |
| >15.0 × 109/L (n, %) | 38 (23.3) |
| Platelet count, median (IQR), (109/L) | 144 (108.0-179.0) |
| ≥100.0 × 109/L, n (%) | 134 (77.9) |
| Immunoglobulins, median (IQR) | |
| IgG, mg/dL | 673.5 (489.5-846.8) |
| IgM, mg/dL | 22.0 (17.0-37.0) |
| IgA, mg/dL | 64.8 (34.3-125.8) |
| Disease/treatment status, n (%) | |
| Treatment-naïve | 40 (23.3) |
| On-therapy | 100 (58.1) |
| Off-therapy | 32 (18.6) |
| Protocols of currently treated, n/N (%) | |
| BTK inhibitors | 59/100 (59.0) |
| Venetoclax ± anti-CD20 antibody† | 39/100 (39.0) |
| RCHOP | 1/100 (1.0) |
| Idelalisib | 1/100 (1.0) |
| Parameter . | Patients with CLL (n = 172) . |
|---|---|
| Age at third vaccination, median (IQR), (y) | 72.1 (68.1-77.7) |
| ≤65 y, n (%) | 33 (19.1) |
| Males n (%) | 121 (69.9) |
| Binet stage,* n/N (%) | |
| A | 32/48 (66.7) |
| B | 11/48 (22.9) |
| C | 5/48 (10.4) |
| IGHV mutational status, n/N (%) | |
| Mutated | 41/112 (36.6) |
| Unmutated | 71/112 (63.4) |
| FISH Döhner scale, n/N (%) | |
| Del(13q) | 38/144 (26.4) |
| No aberration | 33/144 (22.9) |
| Trisomy12 | 23/144 (16.0) |
| Del(11q) | 28/144 (19.4) |
| Del(17p) | 22/144 (15.3) |
| Laboratory parameters | |
| White blood cells, median (IQR), (109/L) | 8.9 (5.4-32.9) |
| Hemoglobin, median (IQR), (g/dL) | 13.2 (12.3-14.5) |
| <10 g/dL, n (%) | 10 (6.3) |
| Absolute lymphocyte count, median (IQR), (109/L) | 2.4 (1.3-12.0) |
| >15.0 × 109/L (n, %) | 38 (23.3) |
| Platelet count, median (IQR), (109/L) | 144 (108.0-179.0) |
| ≥100.0 × 109/L, n (%) | 134 (77.9) |
| Immunoglobulins, median (IQR) | |
| IgG, mg/dL | 673.5 (489.5-846.8) |
| IgM, mg/dL | 22.0 (17.0-37.0) |
| IgA, mg/dL | 64.8 (34.3-125.8) |
| Disease/treatment status, n (%) | |
| Treatment-naïve | 40 (23.3) |
| On-therapy | 100 (58.1) |
| Off-therapy | 32 (18.6) |
| Protocols of currently treated, n/N (%) | |
| BTK inhibitors | 59/100 (59.0) |
| Venetoclax ± anti-CD20 antibody† | 39/100 (39.0) |
| RCHOP | 1/100 (1.0) |
| Idelalisib | 1/100 (1.0) |